Effects of uPA on mesangial matrix changes in the kidney of diabetic rats

Renal Failure

Volumn 36, Issue 8, 2014, Pages 1322-1327

  Cheng, Hui ^a   Chen, Cheng ^a   Wang, Siyuan ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Collagen IV; Diabetic kidney disease; Plasminogen activator inhibitor 1; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor

Indexed keywords

COLLAGEN TYPE 4; CREATININE; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG MECHANISM; EXTRACELLULAR MATRIX; GLOMERULAR STRUCTURE; GLOMERULAR VOLUME; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; KIDNEY SIZE; MALE; MESANGIUM CELL; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; RENAL SYSTEM PARAMETERS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; MESANGIUM; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GLOMERULAR MESANGIUM; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84906718419     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.934694     Document Type: Article

References (13)

1. Cheng H, Chen C, Wang S, Ding G, Shi M. The effects of urokinase-type plasminogen activator (uPA) on cell proliferation and phenotypic transformation of rat mesangial cells induced by high glucose. Diabetes Res Clin Pract. 2014;103(3):489-495.
2. Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci. 2009;14: 2028-2041.
3. Nicholas SB, Aguiniga E, Ren Y, et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005;67(4):1297-1307.
4. Collins SJ, Alexander SL, Lopez-Guisa JM, et al. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol. 2006;104:23-34.
5. Kenichi M, Masanobu M, Takehiko K, et al. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasmino-gen activator inhibitor-1 in diabetic nephropathy in rats: Modulation by angiotensin-converting-enzyme inhibitor. Jf Lab Clin Med 2004;144:69-77.
6. Zhang G, Eddy AA. Urokinase and its receptors in chronic kidney disease. Front Biosci. 2008;13:5462-5478.
7. Tada H, Tsukamoto M, Ishii H, et al. A high concentration of glucose alters the production of tPA, uPA and PAI-1 antigens from human mesangial cells. Diabetes Res Clin Pract. 1994;24: 33-39.
8. Lupia E, Elliot SJ, Lenz O, et al. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: Implications for diabetic nephropathy. Diabetes. 1999;48: 1638-1644.
9. Xi C, Chen X, Sun X, et al. Effects of alterations of glomerular fibrin deposition on renal inflammation in rats at different age stages. J Gerontol A Biol Sci Med Sci. 2005;60: 1099-1110.
10. Cove-Smith A, Hendry BM. The regulation of mesangial cell proliferation. Nephron Exp Nephrol. 2008;108:74-79.
11. Awazu M, Omori S, Ishikura K, et al. The lack of cyclin kinase inhibitor p27Kip1 ameliorates progression of diabetic nephropathy. J Am Soc Nephrol. 2003;14:699-708.
12. Li Y, Knisely JM, Lu W, et al. Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. J Biol Chem. 2002; 277:42366-42371.
13. Zhang G, Kim H, Cai X, et al. Urokinase receptor modulates cellular and angiogenic responses in obstructive uropathy. J Am Soc Nephrol. 2003;14:1254-1271.